Investment in child and adolescent health and development: key messages from Disease Control Priorities

…, I Khan, J Kiamba, J Kim, M Kremer, DS LaMontagne… - The Lancet, 2018 - thelancet.com
The realisation of human potential for development requires age-specific investment
throughout the 8000 days of childhood and adolescence. Focus on the first 1000 days is an …

Colloidal superparticles from nanoparticle assembly

T Wang, D LaMontagne, J Lynch, J Zhuang… - Chemical Society …, 2013 - pubs.rsc.org
… Derek LaMontagne is a PhD graduate student in Prof. Charles Cao's research group in
the Chemistry Department at the University of Florida. He received a BSc (2006) degree in …

Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening

DS LaMontagne, KA Fenton, S Randall… - Sexually transmitted …, 2004 - sti.bmj.com
Background: The phased implementation of the National Chlamydia Screening Programme
(NCSP) began in September 2002. The NCSP offers opportunistic screening for chlamydia …

[HTML][HTML] HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019

…, L Alemany, MS Diallo, OZ Afsar, DS LaMontagne… - Preventive …, 2021 - Elsevier
WHO/UNICEF estimates for HPV vaccination coverage from 2010 to 2019 are analyzed against
the backdrop of the 90% coverage target for HPV vaccination by 2030 set in the recently …

Self-assembled colloidal superparticles from nanorods

…, J Lynch, O Chen, Z Wang, X Wang, D LaMontagne… - Science, 2012 - science.org
… -packed nanorods of a given size (l and d). The superparticle structure is defined with seven
variables (R, H, i, j, n, κ c , and κ d ) that dictate the evolution of superparticle morphology …

[PDF][PDF] Human papillomavirus vaccine delivery strategies that achieved high coverage in low-and middle-income countries

DS LaMontagne, S Barge, N Thi Le… - Bulletin of the World …, 2011 - SciELO Public Health
OBJECTIVE: To assess human papillomavirus (HPV) vaccination coverage after
demonstration projects conducted in India, Peru, Uganda and Viet Nam by PATH and national …

[HTML][HTML] Status of HPV vaccine introduction and barriers to country uptake

KE Gallagher, DS LaMontagne, D Watson-Jones - Vaccine, 2018 - Elsevier
During the last 12 years, over 80 countries have introduced national HPV vaccination programs.
The majority of these countries are high or upper-middle income countries. The barriers …

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart

…, E Escher, RL Silverstein, D Lamontagne… - Circulation …, 2002 - Am Heart Assoc
Growth hormone-releasing peptides (GHRPs) are known as potent growth hormone
secretagogues whose actions are mediated by the ghrelin receptor, a G protein-coupled receptor …

Incidence and reinfection rates of genital chlamydial infection among women aged 16–24 years attending general practice, family planning and genitourinary …

DS Lamontagne, K Baster, L Emmett… - Sexually transmitted …, 2007 - sti.bmj.com
… Guarantor statement: I, D Scott LaMontagne, had full access to all the data in the study
and take responsibility for the integrity of the data and the accuracy of the data analysis. …

[HTML][HTML] Endocannabinoids protect the rat isolated heart against ischaemia

…, JF Bouchard, C Lagneux, D Lamontagne - British journal of …, 2003 - ncbi.nlm.nih.gov
… Panels (c) and (d), represent, respectively the coronary effluent activity of LDH and CK at the
end of the 20-min reperfusion period. * P<0.05 compared with untreated hearts for the entire …